Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-4321 in Autoimmune or Immune-Mediated Diseases
NCT07455578Phase 1Recruiting
- Sponsor
- Seismic Therapeutic
- Start
- Jun 2026
- Primary completion
- Sep 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of S-4321 in rheumatoid arthritis (RA), psoriatic arthritis (PsA), psoriasis and 2 more, sponsored by Seismic Therapeutic. Primary endpoints: Incidence of treatment-emergent adverse events at 31 weeks and Incidence of serious adverse events at 31 weeks. Started Jun 2026; status: recruiting.
02
Drugs
S-4321
03
Conditions
rheumatoid arthritis (RA)psoriatic arthritis (PsA)psoriasiscutaneous lupus erythematosus (CLE)atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07455578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07455578.